A site where you can find recommended contractors for non-clinical testing｜effical " Non-Clinical CROs and Agencies " SNBL INA Ltd.

SNBL INA Ltd.

Table of Contents

Ina Research is a contract research organization (CRO). They provide non-clinical study for pharmaceuticals, medical devices, regenerative medicine products, agricultural chemicals, and chemical substances. They are fully compliant with the latest regulations.

This page showcases key features of Ina Research’s non-clinical service, examples of disease models, and related information.

We hope that you can use this information for a reference when selecting a trusted CRO partner.

eatures of SNBL INA Ltd. Non-Clinical Study Services

GLP-Compliant and Highly Reliable

Ina Research performs non-clinical testing for pharmaceuticals, medical devices, and agrochemicals in accordance with Good Laboratory Practice (GLP) standards.

They have earned a strong reputation for reliability in efficacy, pharmacology, and safety evaluations, maintaining strict quality control under the latest regulatory guidelines.

Specialized pharmacological studies related to the central nervous system and ophthalmology are also available.

Specialized Disease Models

The company offers a wide range of specialized disease models for pharmacological evaluation, particularly in central nervous system and ophthalmology.

These models enable precise assessment of new drug efficacy for target diseases.

Ina Research has also developed proprietary models used in studies for liver diseases and fibrosis.

Accelerated Study Timelines

They provide comprehensive non-clinical service — from screening to Phase I clinical ready — can be achieved as little as in eight months.

their experienced science team can provide rapid, efficient support to deliver high-quality data on schedule.

3 Specialized Pre-clinical CROs for Advanced Drug Discovery

Example Disease Models at SNBL INA Ltd.

It is essential to go through the testing of candidate compounds in animal models that reproduce the target disease before advancing to clinical trials.

However, clinically relevant disease models may not always exist, thus there are demands for animal models with strong clinical correlation.

Below are some examples of disease models offered at Ina Research.

Nephrectomy Model

With the growing number of patients requiring dialysis, animal models of renal failure are essential for studying disease onset, progression, and potential therapeutic agents.

Ina Research conducts pharmacological study with surgically induced partial nephrectomy models.

Diabetic Nephritis Model

Long-term diabetes can impair kidney filtration function, leading to diabetic nephritis. As the condition progresses, it can cause edema and hypertension and ultimately require dialysis.

Ina Research has an established diabetic nephritis model to evaluate therapeutic agents for nephropathy.

Anti-Basement Membrane Antibody Glomerulonephritis Model

This model is for investigating the mechanisms of onset and progression of glomerulonephritis.

Clients can now research in molecular and genetic-level factors in nephritis.

Case Studies

No case studies are currently listed on the official website.

Company Information

Ina Research is a contract research organization expanding its expertise across safety and efficacy evaluation in pharmaceuticals, food, chemicals, and medical devices, while continuously enhancing its unique capabilities.

Address	2148-188 Nishi-Minowa, Ina City, Nagano Prefecture, Japan
Tel	0265-72-6616
Website	https://www.ina-research.co.jp/

3 Recommended Contract Research Organizations for Non-Clinical Studies
— by Target goal and Expertise

In drug discovery, the quality and efficiency of non-clinical studies have a direct impact on clinical success rates, development costs, and overall length of time required in R&D. In recent years, there has been more demand for clinically relevant data, globally accepted reliability, and accurate early-stage screening. Thus, it is more important than ever to select the right CRO (Contract Research Organization) for strategic approach.
In this article, we highlight three CROs with proven technical capabilities, expertise, and long standing track records. These are our TOP 3 choices based on their capabilities and the specific target goals of the researchers for their non-clinical studies.

Pharmacology (Efficacy) Studies
Replicate unknown pathological models and
Discovery to clinically oriented drug evaluation

SMC Laboratories, Inc.

Reference: SMC Laboratories, Inc. official website (https://www.smccro-lab.com/jp/)

SMC Laboratories, Inc. has established a disease models using patented mouse technologies. The company has established proprietary pathological models—particularly in liver disease and fibrosis—and continues to expand their approach across a wide range of models in cancer, inflammation, and metabolic diseases.
From exploratory research to clinically oriented efficacy evaluation, SMC offers customized study designs, dosing strategies, and evaluation analysis tailored to each project. Their collaborative approachallows researchers to discuss and refine study plans together with SMC’s expert scientists.
With flexible small-scale study options and strong technical support, SMC Laboratories, Inc. is an ideal partner for start-ups, biotech ventures, and academic institutions alike.

Consult study design and disease model development
with SMC Laboratories, Inc.

Consult SMC Laboratories
Call us

Safety Studies
Comprehensive Safety Evaluation for FIH Applications

Labcorp Holdings Inc.
(Labcorp Drug Development)

Reference: Labcorp Holdings Inc. official website (https://jp.labcorp.com/)

Labcorp Holdings Inc. provides a fully integrated GLP testing system aligned with international regulatory standards, including FDA, EMA, and PMDA requirements. All studies are conducted under ICH-compliant quality assurance, making it ready for data submission.
The company has extensive expertise in long-term toxicity studies such as Segment I–III reproductive and carcinogenicity studies, as well as 2-year chronic toxicity assessments.
Labcorp Holdings Inc.’s comprehensive approach enables sponsors to efficiently outsource the entire preclinical package from toxicology, toxicokinetic (TK), and safety pharmacology study design to execution. This accelerates a path to First-in-Human (FIH) trials. For most of the global drug developers, this all-in-one service structure minimizes cost, risk, and expedite the time before advancing to clinical phase.

Consult Labcorp Holdings Inc.
Discuss GLP/ICH-compliant study design for your FIH submission.

To labcorp.
Call us

Pharmacokinetic (PK/PD) Studies
High-Precision Bioanalysis for Clinically Predictive PK/PD Evaluation

PhoenixBio Co., Ltd.

Source: PhoenixBio Co., Ltd. Official Website (https://phoenixbio.co.jp/)

PhoenixBio Co., Ltd.offers pharmacokinetic and hepatic metabolism studies using their proprietary PXB-mouse®, a humanized-liver chimeric mouse model. This platform enables the acquisition of data with high clinical correlation in ADME, drug–to-drug interaction studies, bridging the gap between preclinical and clinical stages.
With advanced LC-MS/MS-based bioanalysis, PhoenixBio Co., Ltd. provides aseamless workflow from plasma concentration measurement and metabolite identification to quantitative validation.
The company offersan integrated evaluation analysiscovering pharmacokinetics, hepatotoxicity, and safety with flexibility to accommodate complex modalities such as oligonucleotide and middle-molecule therapeutics. For compounds where hepatic metabolism is a development bottleneck—or where quantitative, reproducible exposure data are critical—PhoenixBio Co., Ltd. delivers unmatched analytical precision and consistency.

Consult Phoenix Bio for PK/PD analysis with a clinical focus

Phoenix Bio.
Call us